Improved pulmonary function and exercise tolerance despite persistent pulmonary fibrosis over 1 year after severe COVID-19 infection
- PMID: 38514184
- PMCID: PMC11044919
- DOI: 10.1136/thorax-2023-220370
Improved pulmonary function and exercise tolerance despite persistent pulmonary fibrosis over 1 year after severe COVID-19 infection
Abstract
We conducted a prospective single-centre cohort study of 104 multi-ethnic severe COVID-19 survivors from the first wave of the pandemic 15 months after hospitalisation. Of those who were assessed at 4 and 15 months, improvement of ground glass opacities correlated with worsened fibrotic reticulations. Despite a high prevalence of fibrotic patterns (64%), pulmonary function, grip strength, 6 min walk distance and frailty normalised. Overall, dyspnoea, cough and exhaustion did not improve and were not correlated with pulmonary function or radiographic fibrosis at 15 months, suggesting non-respiratory aetiologies. Monitoring persistent, and often subclinical, fibrotic interstitial abnormalities will be needed to determine their potential for future progression.
Keywords: COVID-19; clinical epidemiology; imaging/CT MRI; interstitial fibrosis; respiratory measurement; viral infection.
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: MS reports relationships with Boehringer Ingelheim, Genetech, Peer View, France Foundation, Bioclinica, AbbVie and Lung Life AI outside the scope of this study. EAH reports a relationship with VIDA Diagnostics. CKG reports a relationship with Boehringer Ingelheim outside the scope of this study.
Figures

References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical